BiotechTube

E7777 9 mcg/kg

Phase 3Completed
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Persistent or Recurrent Cutaneous T-Cell Lymphoma

Conditions

Persistent or Recurrent Cutaneous T-Cell Lymphoma

Trial Timeline

May 30, 2013 → Dec 14, 2021

NCT ID
NCT01871727

About E7777 9 mcg/kg

E7777 9 mcg/kg is a phase 3 stage product being developed by Eisai for Persistent or Recurrent Cutaneous T-Cell Lymphoma. The current trial status is completed. This product is registered under clinical trial identifier NCT01871727. Target conditions include Persistent or Recurrent Cutaneous T-Cell Lymphoma.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT01871727Phase 3Completed

Competing Products

20 competing products in Persistent or Recurrent Cutaneous T-Cell Lymphoma

See all competitors
ProductCompanyStageHype Score
DE-105 ophthalmic solution + DE-105 ophthalmic solution + Placebo ophthalmic solutionSanten PharmaceuticalPhase 2
52
Phase IIb formulation + Putative phase III formulation + Slow dissolution variant 1 + Slow dissolution variant 2 + Test treatment EAstraZenecaPhase 1
33
AZD0837 + VKA INR 2-3AstraZenecaPhase 2
52
AZD0837 + AspirinAstraZenecaPhase 2
52
Montelukast to placebo + Placebo to montelukastMerckPre-clinical
23
Everolimus + Tamoxifen + Letrozole + Medroxyprogesterone AcetateNovartisPhase 2
52
Formoterol 12 mcg + Fluticasone propionate 100 mcg + Fluticasone propionate 250 mcg + Fluticasone propionate 500 mcg + PlaceboNovartisApproved
85
CertoparinNovartisPhase 3
77
Omalizumab + PlaceboNovartisPhase 3
77
RivastigmineNovartisApproved
85
QAW039 capsules once daily for 28 days + Placebo to QAW039 capsules once daily for 28 days + Fluticasone propionate inhaler twice daily for 28 daysNovartisPhase 2
52
Indacaterol + Placebo to IndacaterolNovartisPhase 2
52
Omalizumab + PlaceboNovartisApproved
85
placebo + iv sildenafilPfizerPhase 3
76
etanercept + placeboPfizerPhase 2
51
SildenafilPfizerPhase 2
51
irbesartan + placeboSanofiApproved
84
iloprostBayerPre-clinical
20
IV Remodulin + PlaceboUnited TherapeuticsPhase 2
49
Nexagon® (lufepirsen) High Dose Concentration + Nexagon® (lufepirsen) Low Dose Concentration + Vehicle + Open-label Nexagon® (lufepirsen)GlaukosPhase 2
49

Other Products from Eisai

MecobalaminApproved
85
MonteplaseApproved
85
E2020 + PlaceboApproved
85
Palonosetron 0.075 mg IV + Dexamethasone 10 mg IV + Promethazine 25 mg IVApproved
85
DonepezilApproved
85